ZA200100943B - Method for making coated gabapentine or pregabaline particles. - Google Patents
Method for making coated gabapentine or pregabaline particles. Download PDFInfo
- Publication number
- ZA200100943B ZA200100943B ZA200100943A ZA200100943A ZA200100943B ZA 200100943 B ZA200100943 B ZA 200100943B ZA 200100943 A ZA200100943 A ZA 200100943A ZA 200100943 A ZA200100943 A ZA 200100943A ZA 200100943 B ZA200100943 B ZA 200100943B
- Authority
- ZA
- South Africa
- Prior art keywords
- process according
- particles
- gabapentine
- chosen
- polymer
- Prior art date
Links
- 239000002245 particle Substances 0.000 title claims description 57
- 238000000034 method Methods 0.000 title claims description 39
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 title claims description 38
- 229960002870 gabapentin Drugs 0.000 title claims description 37
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 title claims description 19
- 150000003951 lactams Chemical class 0.000 claims description 28
- 229920000642 polymer Polymers 0.000 claims description 25
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical class NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims description 19
- 239000011248 coating agent Substances 0.000 claims description 15
- 238000000576 coating method Methods 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- 239000002253 acid Substances 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 238000005507 spraying Methods 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 7
- 239000003960 organic solvent Substances 0.000 claims description 7
- 239000001913 cellulose Substances 0.000 claims description 6
- 229920002678 cellulose Polymers 0.000 claims description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 4
- 239000011230 binding agent Substances 0.000 claims description 4
- 235000003599 food sweetener Nutrition 0.000 claims description 4
- 229940069328 povidone Drugs 0.000 claims description 4
- 239000003765 sweetening agent Substances 0.000 claims description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 3
- 239000002216 antistatic agent Substances 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 210000000214 mouth Anatomy 0.000 claims description 3
- 229920000193 polymethacrylate Polymers 0.000 claims description 3
- 229910052700 potassium Inorganic materials 0.000 claims description 3
- 239000011591 potassium Substances 0.000 claims description 3
- 239000000377 silicon dioxide Substances 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 2
- 230000015556 catabolic process Effects 0.000 claims description 2
- 229920001577 copolymer Polymers 0.000 claims description 2
- 239000000796 flavoring agent Substances 0.000 claims description 2
- 229940074774 glycyrrhizinate Drugs 0.000 claims description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 2
- 239000000314 lubricant Substances 0.000 claims description 2
- 229920005862 polyol Polymers 0.000 claims description 2
- 150000003077 polyols Chemical class 0.000 claims description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 claims description 2
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 claims description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 235000000346 sugar Nutrition 0.000 claims description 2
- 150000008163 sugars Chemical class 0.000 claims description 2
- 239000003232 water-soluble binding agent Substances 0.000 claims description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 239000003826 tablet Substances 0.000 description 27
- 235000019640 taste Nutrition 0.000 description 13
- 238000003860 storage Methods 0.000 description 9
- 230000000873 masking effect Effects 0.000 description 8
- 238000004090 dissolution Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 235000019658 bitter taste Nutrition 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000007857 degradation product Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 229920003134 Eudragit® polymer Polymers 0.000 description 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
- 238000007922 dissolution test Methods 0.000 description 2
- 238000003402 intramolecular cyclocondensation reaction Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 1
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- 239000005449 Avicel CE Substances 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 229920003148 Eudragit® E polymer Polymers 0.000 description 1
- 244000287680 Garcinia dulcis Species 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 229920003085 Kollidon® CL Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 101710150104 Sensory rhodopsin-1 Proteins 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- NEDGUIRITORSKL-UHFFFAOYSA-N butyl 2-methylprop-2-enoate;2-(dimethylamino)ethyl 2-methylprop-2-enoate;methyl 2-methylprop-2-enoate Chemical compound COC(=O)C(C)=C.CCCCOC(=O)C(C)=C.CN(C)CCOC(=O)C(C)=C NEDGUIRITORSKL-UHFFFAOYSA-N 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 238000005243 fluidization Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229940072228 neurontin Drugs 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 229920003176 water-insoluble polymer Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9810091A FR2781793B1 (fr) | 1998-08-03 | 1998-08-03 | Procede de fabrication de granules de gabapentine enrobes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200100943B true ZA200100943B (en) | 2001-09-05 |
Family
ID=9529443
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200100943A ZA200100943B (en) | 1998-08-03 | 2001-02-02 | Method for making coated gabapentine or pregabaline particles. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US6488964B2 (fr) |
| EP (1) | EP1100467A1 (fr) |
| JP (1) | JP2002522375A (fr) |
| CN (1) | CN1321083A (fr) |
| AR (1) | AR021746A1 (fr) |
| AU (1) | AU742701B2 (fr) |
| CA (1) | CA2338173A1 (fr) |
| FR (1) | FR2781793B1 (fr) |
| NZ (1) | NZ509980A (fr) |
| PE (1) | PE20001030A1 (fr) |
| WO (1) | WO2000007568A1 (fr) |
| ZA (1) | ZA200100943B (fr) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6539213B1 (en) * | 1999-06-14 | 2003-03-25 | Time Domain Corporation | System and method for impulse radio power control |
| US6294198B1 (en) | 1999-08-24 | 2001-09-25 | Purepac Pharmaceutical Co. | Pharmaceutical tablet formulation containing gabapentin with improved physical and chemical characteristics and method of making the same |
| YU95302A (sh) * | 2000-06-16 | 2006-05-25 | Teva Pharmaceutical Industries Ltd. | Stabilni gabapentin koji ima ph u kontrolisanom rasponu |
| ES2193008T3 (es) | 2000-06-16 | 2004-07-01 | Teva Pharmaceutical Industries Ltd. | Gabapentina estable que contiene mas de 20 ppm de iones de cloro. |
| EP1384473A1 (fr) * | 2000-06-16 | 2004-01-28 | Teva Pharmaceutical Industries Ltd. | Gabapentin stable contenant plus de 20 ppm d'ions chlore |
| EP1430893A1 (fr) * | 2000-06-16 | 2004-06-23 | Teva Pharmaceutical Industries Ltd. | Gabapentin stable contenant plus de 20 ppm d'ions chlore |
| US7056951B2 (en) * | 2000-09-26 | 2006-06-06 | Mutual Pharmaceutical Co., Inc. | Stable solid dosage forms of amino acids and processes for producing same |
| US7022678B2 (en) * | 2001-03-30 | 2006-04-04 | Warner-Lambert Company | Pregabalin lactose conjugates |
| US20060159743A1 (en) * | 2001-10-25 | 2006-07-20 | Depomed, Inc. | Methods of treating non-nociceptive pain states with gastric retentive gabapentin |
| US20070184104A1 (en) * | 2001-10-25 | 2007-08-09 | Depomed, Inc. | Gastric retentive gabapentin dosage forms and methods for using same |
| US7612112B2 (en) * | 2001-10-25 | 2009-11-03 | Depomed, Inc. | Methods of treatment using a gastric retained gabapentin dosage |
| TWI312285B (en) | 2001-10-25 | 2009-07-21 | Depomed Inc | Methods of treatment using a gastric retained gabapentin dosage |
| CN1668284A (zh) * | 2002-06-07 | 2005-09-14 | 兰贝克赛实验室有限公司 | 加巴喷丁的缓释口服剂型 |
| FR2851734B1 (fr) * | 2003-02-28 | 2006-06-09 | Galenix Innovations | Procede pour la fabrication d'une composition pharmaceutique sous la forme de comprimes contenant un fibrate et comprimes obtenus selon le procede |
| ATE465718T1 (de) | 2003-05-02 | 2010-05-15 | Globopharm Pharmazeutische Pro | Feste pharmazeutische zubereitung enthaltend levothyroxin- und/oder liothyroninsalze |
| WO2005046566A2 (fr) * | 2003-08-04 | 2005-05-26 | Sun Pharmaceutical Industries Limited | Composition pharmaceutique stable |
| CN1867326A (zh) * | 2003-09-03 | 2006-11-22 | 兰贝克赛实验室有限公司 | 加巴喷丁的缓释口服片剂及其制备方法 |
| ITMI20032399A1 (it) * | 2003-12-09 | 2005-06-10 | Zambon Spa | Composizione farmaceutica contenente gabapentina. |
| AU2006206423A1 (en) * | 2005-01-21 | 2006-07-27 | Pharmanova Inc. | Pharmaceutical formulations and methods of use |
| WO2006108151A1 (fr) * | 2005-04-06 | 2006-10-12 | Teva Pharmaceutical Industries Ltd. | Formes cristallines de pregabaline |
| US20070066846A1 (en) * | 2005-04-11 | 2007-03-22 | Asher Maymon | Process for making (S)-Pregabalin |
| US7488846B2 (en) * | 2005-04-11 | 2009-02-10 | Teva Pharmaceuical Industries Ltd. | Pregabalin free of lactam and a process for preparation thereof |
| KR20090019016A (ko) * | 2005-05-10 | 2009-02-24 | 테바 파마슈티컬 인더스트리즈 리미티드 | 3-카르바모일메틸-5-메틸 헥산산의 광학 분할 |
| WO2006122258A1 (fr) * | 2005-05-10 | 2006-11-16 | Teva Pharmaceutical Industries Ltd. | Procede pour preparer de la pregabaline et des sels de celle-ci |
| WO2006121557A1 (fr) * | 2005-05-10 | 2006-11-16 | Teva Pharmaceutical Industries Ltd. | Pregabaline exempte de lactame et son procede de preparation |
| MX2007000525A (es) * | 2005-05-10 | 2007-03-28 | Teva Pharma | Pregabalina libre de acido isobutilglutarico y un proceso para la preparacion de ella. |
| US7446220B2 (en) * | 2005-09-19 | 2008-11-04 | Teva Pharmaceutical Industries Ltd. | Asymmetric synthesis of (S)-(+)-3-(aminomethyl)-5-methylhexanoic acid |
| US20090176882A1 (en) * | 2008-12-09 | 2009-07-09 | Depomed, Inc. | Gastric retentive gabapentin dosage forms and methods for using same |
| WO2007139933A2 (fr) * | 2006-05-24 | 2007-12-06 | Teva Pharmaceutical Industries Ltd. | Procédés pour la préparation d'acide r-(+)-3-(carbamoyl méthyl)-5-méthylhexanoïque et de sels de celui-ci |
| EP2071032A3 (fr) * | 2006-05-31 | 2009-07-08 | Teva Pharmaceutical Industries Ltd | Utilisation d'une résolution enzymatique pour la préparation d'intermédiaires de la prégabaline |
| EP1912931A2 (fr) * | 2006-05-31 | 2008-04-23 | Teva Pharmaceutical Industries Ltd. | Préparation de (s)-prégabaline nitrile |
| GB0616794D0 (en) * | 2006-08-24 | 2006-10-04 | Arrow Int Ltd | Solid dosage form |
| US8153120B2 (en) | 2007-03-22 | 2012-04-10 | Dendreon Corporation | Methods for inducing a natural killer (NK) cell-mediated immune response and for increasing NK cell activity |
| KR101036536B1 (ko) * | 2007-03-22 | 2011-05-24 | 테바 파마슈티컬 인더스트리즈 리미티드 | (ｓ)-(+)-3-(아미노메틸)-5-메틸 헥산산의 합성 |
| US20090137842A1 (en) * | 2007-10-03 | 2009-05-28 | Vollerner Yuri | Pregabalin -4-eliminate, pregabalin 5-eliminate, their use as reference marker and standard, and method to produce pregabalin containing low levels thereof |
| WO2009066325A1 (fr) * | 2007-11-23 | 2009-05-28 | Lupin Limited | Compositions pharmaceutiques de prégabaline à libération contrôlée |
| SG176464A1 (en) | 2008-05-09 | 2011-12-29 | Agency Science Tech & Res | Diagnosis and treatment of kawasaki disease |
| EP2297090A1 (fr) * | 2008-06-23 | 2011-03-23 | Teva Pharmaceutical Industries Ltd. | Synthèse enzymatique stéréosélective de l ester (s) ou (r)-isobutylglutarique |
| WO2010150221A1 (fr) | 2009-06-25 | 2010-12-29 | Wockhardt Research Centre | Compositions pharmaceutiques de prégabaline de saveur masquée |
| TR200909613A1 (tr) * | 2009-12-22 | 2011-07-21 | Sanovel İlaç San. Ve Ti̇c. A.Ş. | Pregabalinin farmasötik bileşimleri. |
| HU230031B1 (hu) | 2010-03-01 | 2015-05-28 | Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság | Pregabalint és izomaltot tartalmazó stabilizált gyógyszerkészítmény |
| WO2013100873A1 (fr) * | 2011-12-19 | 2013-07-04 | Mahmut Bilgic | Formulation pharmaceutique de prégabaline (taille de particules 300-2500 micromètres) |
| KR102221846B1 (ko) * | 2014-04-07 | 2021-02-26 | 영진약품 주식회사 | 안정성이 개선된 프레가발린을 함유하는 약제학적 조성물 및 이의 제조방법 |
| JP6919119B2 (ja) * | 2017-01-23 | 2021-08-18 | 日新製薬株式会社 | ３位が置換されたγ−アミノ酪酸誘導体を含有する圧縮固形医薬組成物。 |
| DK3760190T3 (da) | 2019-07-03 | 2023-09-04 | Alvogen Inc | Tabletter af pregabalin med forlænget frigivelse, fremgangsmåde til fremstilling og fremgangsmåde til anvendelse deraf |
| CN112843015A (zh) * | 2021-04-08 | 2021-05-28 | 海南鑫开源医药科技有限公司 | 一种加巴喷丁胶囊制剂及其制备方法 |
| GB2625579A (en) * | 2022-12-21 | 2024-06-26 | Novumgen Ltd | An orally disintegrating tablet containing gabapentin or pharmaceutically acceptable salts thereof and the process of preparing the same |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2460891C2 (de) | 1974-12-21 | 1982-09-23 | Gödecke AG, 1000 Berlin | 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
| CH658188A5 (de) * | 1984-03-23 | 1986-10-31 | Ciba Geigy Ag | Lagerstabile schnellzerfallende pharmazeutische presslinge. |
| SE457326B (sv) * | 1986-02-14 | 1988-12-19 | Lejus Medical Ab | Foerfarande foer framstaellning av en snabbt soenderfallande kaerna innehaallande bl a mikrokristallin cellulosa |
| JPS63188621A (ja) * | 1987-01-30 | 1988-08-04 | Taisho Pharmaceut Co Ltd | 矯味経口製剤 |
| EP0458751A1 (fr) * | 1990-05-25 | 1991-11-27 | Warner-Lambert Company | Système à libération d'amino-acides cycliques avec gôut, texture et compressibilité améliorés |
| CA2068402C (fr) * | 1991-06-14 | 1998-09-22 | Michael R. Hoy | Enrobage pour masquer le gout pouvant etre utilise dans des comprimes pharmaceutiques croquables |
| US5464632C1 (en) * | 1991-07-22 | 2001-02-20 | Prographarm Lab | Rapidly disintegratable multiparticular tablet |
| FR2679451B1 (fr) * | 1991-07-22 | 1994-09-09 | Prographarm Laboratoires | Comprime multiparticulaire a delitement rapide. |
| JPH0710747A (ja) * | 1993-04-28 | 1995-01-13 | Takeda Chem Ind Ltd | 固形製剤およびその製造方法 |
| SK283711B6 (sk) * | 1994-07-27 | 2003-12-02 | Warner-Lambert Company | Liečivo na liečenie úzkosti a panického strachu |
-
1998
- 1998-08-03 FR FR9810091A patent/FR2781793B1/fr not_active Expired - Lifetime
-
1999
- 1999-07-23 AU AU49160/99A patent/AU742701B2/en not_active Expired
- 1999-07-23 JP JP2000563254A patent/JP2002522375A/ja active Pending
- 1999-07-23 EP EP99932956A patent/EP1100467A1/fr not_active Ceased
- 1999-07-23 CN CN99811672A patent/CN1321083A/zh active Pending
- 1999-07-23 NZ NZ509980A patent/NZ509980A/en not_active IP Right Cessation
- 1999-07-23 WO PCT/FR1999/001811 patent/WO2000007568A1/fr not_active Application Discontinuation
- 1999-07-23 CA CA002338173A patent/CA2338173A1/fr not_active Abandoned
- 1999-08-02 PE PE1999000772A patent/PE20001030A1/es not_active Application Discontinuation
- 1999-08-03 AR ARP990103853A patent/AR021746A1/es unknown
-
2001
- 2001-02-02 ZA ZA200100943A patent/ZA200100943B/en unknown
- 2001-02-05 US US09/777,490 patent/US6488964B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CA2338173A1 (fr) | 2000-02-17 |
| AU4916099A (en) | 2000-02-28 |
| FR2781793A1 (fr) | 2000-02-04 |
| WO2000007568A1 (fr) | 2000-02-17 |
| JP2002522375A (ja) | 2002-07-23 |
| PE20001030A1 (es) | 2000-10-12 |
| AR021746A1 (es) | 2002-08-07 |
| EP1100467A1 (fr) | 2001-05-23 |
| US6488964B2 (en) | 2002-12-03 |
| FR2781793B1 (fr) | 2001-07-20 |
| NZ509980A (en) | 2003-07-25 |
| AU742701B2 (en) | 2002-01-10 |
| US20020012679A1 (en) | 2002-01-31 |
| CN1321083A (zh) | 2001-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200100943B (en) | Method for making coated gabapentine or pregabaline particles. | |
| JP6764959B2 (ja) | 医薬組成物 | |
| US6660382B2 (en) | Process for manufacturing coated granules with masked taste and immediate release of the active principle | |
| EP1976492B2 (fr) | Système d'administration de médicaments comprenant des médicaments faiblement basiques et des acides organiques | |
| US20090311321A1 (en) | Oral disintegrating tablet having masked bitter taste and method for production thereof | |
| SG184951A1 (en) | Method for preparing pharmaceutical compositions intended for oral administration comprising one or more active ingredients and the compositions comprising same | |
| US20100183730A1 (en) | High dose composition of ursodeoxycholic acid | |
| EP1587496B1 (fr) | Particules presentant un enrobage de masquage du gout, procede de preparation associe et comprimes orodispersibles contenant lesdites particules enrobees | |
| ES2700364T3 (es) | Comprimido de disgregación oral y método para su fabricación | |
| CN107530294B (zh) | 含有质子泵抑制剂的肠溶包衣丸剂 | |
| US20110300224A1 (en) | Taste masked dosage form of pharmaceutically acceptable salt of escitalopram | |
| EP1911444A1 (fr) | Particule fine enrobee contenant un medicament pour une preparation se desagregeant dans la bouche et procede de production de celle-ci | |
| KR20200106607A (ko) | 오셀타미비르 함유 의약 조성물 | |
| US7815939B2 (en) | Coated fine particles containing drug for intrabuccally fast disintegrating dosage forms | |
| CN112353802A (zh) | 一种富马酸伏诺拉生掩味组合物及其应用 | |
| CN100588390C (zh) | 掩蔽味道的包衣颗粒、其制备方法和含有所述包衣颗粒的口腔分散片 | |
| CN114340601A (zh) | 掩盖了令人不快的味道的颗粒剂及其制造方法 | |
| KR20210003323A (ko) | 탐수로신 또는 이의 염산염 함유 제약 조성물 및 이의 제조방법 | |
| JP2022514040A (ja) | 耐酸性に優れたタムスロシン塩酸塩含有医薬組成物及びその製造方法 | |
| KR20040011087A (ko) | 불쾌한 맛과 향을 차폐할 수 있는 록시스로마이신 과립의제조방법 | |
| CN112076168A (zh) | 一种罗红霉素分散片及其制备方法 | |
| CN111432806A (zh) | 包含沙芬酰胺的药物组合物 | |
| MXPA01001300A (en) | Method for making coated gabapentine or pregabaline particles | |
| KR20040023167A (ko) | 쓴 맛이 은폐된 세푸록심악세틸 제제의 제약조성물 및 그의 제조방법 |